Pfizer Norvasc Goes Before Advisory Cmte. April 5 For Review Of ALLHAT Supplement

FDA's Cardio-Renal Advisory Committee will review supplemental indications for reduction of risk of fatal coronary heart disease, non-fatal myocardial infarction and stroke.